Julhash U Kazi (L Rönnstrand)

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2013-2023
Publications (10 Years): 21

Top Venues

International journal of molecular sciences

Blood cancer journal

Oncogene

Scientific reports

Lund University

Inha University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Lund University Jan 1o 2015 - Nov 13o 2016

Sweden

Assistant Professor :: Laboratory Medicine Lund

Education History

Inha University Sep 1o 2005 - Aug 24o 2009

South Korea

PHD :: Chemistry (Biomedical Research)

Publications

Kinjal Shah, Lina Al Ashiri, Ahmad Nasimian, Mehreen Ahmed, Julhash U Kazi
Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine Signaling. International journal of molecular sciences 24 (5) (2023)
Kinjal Shah, Ahmad Nasimian, Mehreen Ahmed, Lina Al Ashiri, Linn Denison, Wondossen Sime, Katerina Bendak, Iryna Kolosenko, Valentina Siino, Fredrik Levander, Caroline Palm-Apergi, Ramin Massoumi, Richard B Lock, Julhash U Kazi
PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia. Blood cancer journal 13 (1) (2023)
Kinjal Shah, Lina Al Ashiri, Ahmad Nasimian, Mehreen Ahmed, Julhash U Kazi
Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine Signaling. International journal of molecular sciences 24 (5) (2023)
Julhash U Kazi, Lina Al Ashiri, Rituraj Purohit, Lars Rönnstrand
Understanding the Role of Activation Loop Mutants in Drug Efficacy for FLT3-ITD. Cancers 15 (22) (2023)
Ahmad Nasimian, Lina Al Ashiri, Mehreen Ahmed, Hongzhi Duan, Xiaoyue Zhang, Lars Rönnstrand, Julhash U Kazi
A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia. International journal of molecular sciences 24 (4) (2023)
Kinjal Shah, Lina Al Ashiri, Ahmad Nasimian, Mehreen Ahmed, Julhash U Kazi
Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine Signaling. International journal of molecular sciences 24 (5) (2023)
Ahmad Nasimian, Lina Al Ashiri, Mehreen Ahmed, Hongzhi Duan, Xiaoyue Zhang, Lars Rönnstrand, Julhash U Kazi
A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia. International journal of molecular sciences 24 (4) (2023)
Ahmad Nasimian, Lina Al Ashiri, Mehreen Ahmed, Hongzhi Duan, Xiaoyue Zhang, Lars Rönnstrand, Julhash U Kazi
A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia. International journal of molecular sciences 24 (4) (2023)
Ahmad Nasimian, Lina Al Ashiri, Mehreen Ahmed, Hongzhi Duan, Xiaoyue Zhang, Lars Rönnstrand, Julhash U Kazi
A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia. International journal of molecular sciences 24 (4) (2023)
Kinjal Shah, Amr Al-Haidari, Jianmin Sun, Julhash U Kazi
T cell receptor (TCR) signaling in health and disease. Signal transduction and targeted therapy 6 (1) (2021)
Kinjal Shah, Mehreen Ahmed, Julhash U Kazi
The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia. NPJ precision oncology 5 (1) (2021)
Julhash U Kazi
Mechanisms of Anticancer Therapy Resistance: The Role of Cancer Stem Cells. International journal of molecular sciences 21 (23) (2020)
Sausan A Moharram, Kinjal Shah, Fatima Khanum, Lars Rönnstrand, Julhash U Kazi
The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia. Blood cancer journal 9 (2) (2019)
Julhash U Kazi, Lars Rönnstrand
FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications. Physiological reviews 99 (3) (2019)
Sausan A Moharram, Kinjal Shah, Fatima Khanum, Lars Rönnstrand, Julhash U Kazi
Correction: The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia. Blood cancer journal 9 (8) (2019)
Rohit A Chougule, Kinjal Shah, Sausan A Moharram, Johan Vallon-Christersson, Julhash U Kazi
Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation. NPJ genomic medicine 4 (2019)
Tianfeng Li, Yi Deng, Yu Shi, Ruijun Tian, Yonglong Chen, Lin Zou, Julhash U Kazi, Lars Rönnstrand, Bo Feng, Sun On Chan, Wai Yee Chan, Jianmin Sun, Hui Zhao
Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma. Oncogene 37 (47) (2018)
Axel Hyrenius-Wittsten, Mattias Pilheden, Helena Sturesson, Jenny Hansson, Michael P Walsh, Guangchun Song, Julhash U Kazi, Jian Liu, Ramprasad Ramakrishan, Cristian Garcia-Ruiz, Stephanie Nance, Pankaj Gupta, Jinghui Zhang, Lars Rönnstrand, Anne Hultquist, James R Downing, Karin Lindkvist-Petersson, Kajsa Paulsson, Marcus Järås, Tanja A Gruber, Jing Ma, Anna K Hagström-Andersson
De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia. Nature communications 9 (1) (2018)
Kinjal Shah, Sausan A Moharram, Julhash U Kazi
Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression. Clinical epigenetics 10 (2018)
Kaja Rupar, Sausan A Moharram, Julhash U Kazi, Lars Rönnstrand
SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation. Scientific reports 8 (1) (2018)
Alissa Marhäll, Julhash U Kazi, Lars Rönnstrand
The Src family kinase LCK cooperates with oncogenic FLT3/ITD in cellular transformation. Scientific reports 7 (1) (2017)
J Sun, S Mohlin, A Lundby, J U Kazi, U Hellman, S Påhlman, J V Olsen, Julhash U Kazi
The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner. Oncogene 33 (46) (2013)

Julhash U Kazi.css-eqlu8i{font-size:small;padding-left:4px;} (L Rönnstrand)

Publication Activity (10 Years)

Top Topics

Top Venues

Julhash U Kazi (L Rönnstrand)